Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7013212 | 0.88 | LCK (0.57) | LCKIDH1 | |
| SCHEMBL7590193 | 0.88 | LCK (0.57) | LCKIDH1 | |
| SCHEMBL7021834 | 0.88 | LCK (0.57) | LCKIDH1 | |
| SCHEMBL7102009 | 0.86 | LCK (0.55) | LCKIDH1 | |
| SCHEMBL7018133 | 0.86 | LCK (0.55) | LCKIDH1 | |
| SCHEMBL7592889 | 0.84 | LCK (0.53) | LCKIDH1 | |
| SCHEMBL7021056 | 0.84 | LCK (0.53) | LCKIDH1 | |
| SCHEMBL7504210 | 0.83 | LCK (1.00) | LCK | |
| SCHEMBL7552175 | 0.83 | LCK (0.64) | LCK | |
| SCHEMBL7021368 | 0.83 | LCK (0.64) | LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |
| EP-1206265-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |